Beximco Launches World’s First Molnupiravir Generic
Generic Version Of MSD’s Oral Therapy For COVID-19 To Be Marketed As Emorivir
Executive Summary
Bangladesh’s Beximco has launched the world’s first molnupiravir generic, to be marketed as Emorivir, following an emergency use authorization by the local regulator. The company told Generics Bulletin it was able to manufacture and sell its version of the MSD oral COVID-19 treatment thanks to the WTO’s TRIPS waiver for less economically developed countries.